0000950170-23-052171.txt : 20231005
0000950170-23-052171.hdr.sgml : 20231005
20231005151354
ACCESSION NUMBER: 0000950170-23-052171
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231003
FILED AS OF DATE: 20231005
DATE AS OF CHANGE: 20231005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38360
FILM NUMBER: 231311126
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Solid Biosciences Inc.
CENTRAL INDEX KEY: 0001707502
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 900943402
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
BUSINESS PHONE: 617-337-4680
MAIL ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
FORMER COMPANY:
FORMER CONFORMED NAME: Solid Biosciences, LLC
DATE OF NAME CHANGE: 20170524
4
1
ownership.xml
4
X0508
4
2023-10-03
0001707502
Solid Biosciences Inc.
SLDB
0001197032
SMITH IAN F
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR
CHARLESTOWN
MA
02129
true
false
false
false
false
Common Stock
2023-10-03
4
M
false
15569
A
84378
D
Restricted Stock Units
2023-10-03
4
M
false
15569
0
D
Common Stock
15569
15570
D
Restricted units convert to common on a one-for-one basis.
The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.
/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith
2023-10-05